SEC FORM 13F-HR/A

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F COVER PAGE

OMB APPROVAL
OMB Number:3235-0006
Expires:Oct 31, 2018
Estimated average burden
hours per response:23.8

Report for the Calendar Year or Quarter Ended:09-30-2021
Check here if AmendmentXAmendment Number:1
This Amendment (Check only one.):Xis a restatement.
  adds new holdings entries.
Institutional Investment Manager Filing this Report:
Name:JOHNSON & JOHNSON
Address:ONE JOHNSON & JOHNSON PLZ
NEW BRUNSWICK, NJ  08933
Form 13F File Number:028-20072

The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Person Signing this Report on Behalf of Reporting Manager:
Name:Matthew Orlando
Title:Secretary
Phone:732-524-2455
Signature, Place, and Date of Signing:
/s/ Matthew OrlandoNew BrunswickNJ11-16-2021
[Signature][City, State][Date]
This amendment is being filed solely to include Johnson & Johnson UK Treasury Company Limited as an Included Manager and to indicate in the Information Table that a previously-reported position is held by this Manager.
Report Type (Check only one.):
X13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)
  13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)
  13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).)
Form 13F Summary Page
Report Summary:
Number of Other Included Managers:2
Form 13F Information Table Entry Total:25
Form 13F Information Table Value Total:1,139,968
(thousands)
List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report.
[If there are no entries in this list, state “NONE” and omit the column headings and list entries.]
No.Form 13F File NumberName
1028-20073Johnson & Johnson Innovation - JJDC, Inc.
2 Johnson & Johnson UK Treasury Company Limited

SEC FORM 13-F Information Table

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number:3235-0006
Expires:Oct 31, 2018
Estimated average burden
hours per response:23.8

COLUMN 1COLUMN 2COLUMN 3COLUMN 4COLUMN 5COLUMN 6COLUMN 7COLUMN 8
VALUESHRS ORSH/PUT/INVESTMENTOTHERVOTING AUTHORITY
NAME OF ISSUERTITLE OF CLASSCUSIP(x$1000)PRN AMTPRNCALLDISCRETIONMANAGERSOLESHAREDNONE
ADICET BIO, INC.COM0070021085,715728,944SH DFND10728,9440
ALDEYRA THERAPEUTICS, INC.COM01438T1063,467394,834SH DFND10394,8340
ARROWHEAD PHARMACEUTICALSCOM04280A100203,5763,260,869SH DFND103,260,8690
BIOMX INC.COM09090D1036,5282,133,402SH DFND102,133,4020
CASTLIGHT HEALTH INC.CL B14862Q1001,274811,295SH DFND10811,2950
CATALYST BIOSCIENCES, INC.COM14888D20827566,951SH DFND1066,9510
CUE HEALTH, INC.COM22979010065,5325,548,864SH DFND105,548,8640
CVRX, INC.COM12663810557,8173,495,575SH DFND103,495,5750
FATE THERAPEUTICS, INC.COM31189P102200,2773,379,064SH DFND103,379,0640
FUSION PHARMACEUTICALS INC.COM36118A10029,0703,670,516SH DFND103,670,5160
GRAYBUG VISION, INC.COM SHS38942Q10316449,547SH DFND1049,5470
LEGEND BIOTECH CORPORATIONSPONSORED ADS52490G10282,3711,629,173SH DFND101,629,1730
MEIRAGTX HOLDINGS PLCCOMG5966510238,2032,898,550SH DFND102,898,5500
NEUROPACE, INC.COM64128810587955,435SH DFND1055,4350
PHASEBIO PHARMACEUTICALS, INC.COM7172241094,9981,607,044SH DFND101,607,0440
POINT BIOPHARMA GLOBAL INC.COM7305411097,6901,000,000SH DFND101,000,0000
PROCEPT BIOROBOTICS CORPORATIONCOM74276L10538,8551,018,478SH DFND101,018,4780
PROTAGONIST THERAPEUTICS INC.COM74366E10243,4002,449,183SH DFND102,449,1830
PULMONX CORPORATIONCOM7458481012035,639SH DFND105,6390
SENSEONICS HOLDINGS, INC.COM81727U10518554,621SH DFND1054,6210
TRACON PHARMACEUTICALS, INC.COM89237H20932584,003SH DFND1084,0030
VOR BIOPHARMA, INC.COM92903310816,8511,074,658SH DFND101,074,6580
ZYMERGEN INC.COM98985X10021816,553SH DFND1016,5530
ILLUMINA, INC.COM452327109328,613810,170SH DFND20810,1700
SOMALOGIC, INC.COM83444K1053,482281,052SH DFNDN/A0281,0520